{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"sCR (stringent complete response)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"9"}]}],"title":"VGPR (very good partial response)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"9"}]}],"title":"PR (partial response)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}],"title":"SD (stable disease)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"}],"units":"Participants"}],"description":"Objective response rate, defined according to the International Myeloma Working Group (IMWG) criteria as greater then or equal to a Partial Response (PR). The best response was recorded. The IMWG criteria can be found here: imwg.myeloma.org/international-myeloma-working-group-imwg-uniform-response-criteria-for-multiple-myeloma/","groups":[{"description":"26 patients started the treatment phase. Per protocol, completion of the treatment phase was defined as removal from treatment due to progression, or to pursue an alternative treatment (either a stem cell transplant, or further consolidation chemotherapy in pursuit of a transplant). 25 of the 26 patients enrolled were accessible for response/progression, as one patient expired prior to first response assessment and could not be included in the analysis.","id":"OG000","title":"T-BiRD Therapy (All Patients)"}],"paramType":"NUMBER","populationDescription":"25 of the 26 patients enrolled were accessible for response/progression, as one patient expired prior to first response assessment and could not be included in the analysis.","reportingStatus":"POSTED","timeFrame":"This was collected from patients for their duration on study treatment. Only the best response was recorded. Best responses were reported at any point of the study, from start of treatment up until removal of study, which occurred up to 57.4 cycles","title":"Effect of Drug Combination on Multiple Myeloma","type":"PRIMARY","unitOfMeasure":"participants"}